Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00285844 · ClinicalTrials.gov registry record · Phase 1

Integrating the Genetic and Metabolic Faces of Obesity

A Phase 1 study, sponsored by Stanford University.

Completed
Registry status
Phase 1
Development phase
88
Enrollment target

NCT00285844: Completed Phase 1 study, sponsored by Stanford University.

NCT00285844 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00285844, a Phase 1 study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 1
Development phase
88 participants
Enrollment target

Study Summary

The goal of this study is to determine why some obese individuals develop insulin resistance and others do not. We hypothesize that an impairment in differentiation of fat cells (adipocytes) is responsible for the development of insulin resistance in select obese individuals. This study will evaluate obese individuals at baseline with respect to characteristics of adipocytes, including gene expression, and will then entail randomizing subjects to either weight loss or treatment with an insulin sensitizing drug (pioglitazone). Changes in insulin resistance will be associated with changes in adipocyte morphology and gene expression.

Interventions

  • BEHAVIORAL weight loss
  • DRUG thiazolidinedione

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2005-10
Est. Completion 2012-10
Phase Phase 1
Stanford University

1,744 total trials

What the finished NCT00285844 record still lists

NCT00285844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).

The record links to 0 conditions, and to 2 interventions - of which weight loss is the first listed.

NCT00285844 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00285844 about?

NCT00285844 is a clinical study titled "Integrating the Genetic and Metabolic Faces of Obesity". The goal of this study is to determine why some obese individuals develop insulin resistance and others do not. We hypothesize that an impairment in differentiation of fat cells (adipocytes) is responsible for the development of insulin resistance in select obese individuals. This study will evaluat...

What is the current status of trial NCT00285844?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2005-10. Estimated completion is 2012-10.

What interventions are being tested in trial NCT00285844?

The interventions under investigation include: weight loss (BEHAVIORAL), thiazolidinedione (DRUG).

Who is sponsoring clinical trial NCT00285844?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00285844's enrollment target sits among peer trials

88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00285844, the US trial registry maintained by the National Library of Medicine. NCT00285844 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.